Justin Byers | AI, Data Infrastructure, and the Future of Biologics Development
Justin Byers joins Executive Insights for Life Sciences Innovators to discuss the data infrastructure required to make AI more useful in biologics development and manufacturing. The conversation explores fragmented process data, knowledge loss during tech transfer and organizational handoffs, and how Axio BioPharma is connecting process data across sites, systems, and partners.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Justin Byers discusses why the value of AI in biologics development and manufacturing depends on having connected, usable process data. The conversation examines how fragmented information and knowledge loss can limit AI’s impact, and how Axio BioPharma is combining real laboratory execution with a federated approach to connecting data across sites, systems, and partners.
Key Themes
- Why fragmented process data can limit the value of AI in biologics development and manufacturing
- How knowledge is lost during technology transfer and organizational handoffs
- The importance of connecting process data across sites, systems, and partners
- Axio BioPharma’s federated approach to data infrastructure
- Combining real laboratory execution with connected process data
- Building the infrastructure needed for more useful AI applications in life sciences
Why This Matters for Life Sciences Leaders
For life sciences leaders, AI adoption is increasingly becoming a question of infrastructure rather than simply technology. When critical process knowledge is fragmented across systems, sites, and organizations, even sophisticated AI tools can struggle to deliver meaningful value. The ability to connect data while preserving the context of real laboratory execution can help organizations improve knowledge transfer, strengthen development and manufacturing workflows, and create a more useful foundation for AI-driven decision-making.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
